Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21895805 | 0.97 | TSHR (0.60) | LMNANFKB1TSHRPMP22GSTK1 | |
| SCHEMBL1032258 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL26919967 | 0.90 | LMNA (0.50) | LMNANFKB1TSHRPMP22GSTK1 | |
| SCHEMBL27804244 | 0.82 | LMNA (0.55) | LMNANFKB1TSHRPMP22GSTK1 | |
| SCHEMBL1032360 | 0.80 | — | — | |
| SCHEMBL7782357 | 0.80 | LMNA (0.52) | LMNANFKB1TSHRPMP22GSTK1 | |
| SCHEMBL22826568 | 0.80 | MAPT (0.59) | LMNANFKB1TSHRPMP22GSTK1 | |
| SCHEMBL21895793 | 0.78 | TSHR (0.55) | LMNANFKB1TSHRPMP22GSTK1 | |
| Hydrochloric Acid SCHEMBL7410571 | 0.78 | — | — | |
| Adipic Acid SCHEMBL2244299 | 0.76 | LMNA (1.00) | LMNANFKB1TSHRPMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112042016-B | Lithium cobalt oxide secondary battery for high voltage applications comprising a fluorinated electrolyte and a positive electrode material | 尤米科尔公司 | 2023-10-20 | — | — | CN | claimed |
| CN-114762147-A | Electrolyte compositions with fluorinated acyclic esters and fluorinated cyclic carbonates | 索尔维公司 | 2022-07-15 | — | — | CN | claimed |
| CN-112186247-A | Non-aqueous electrolyte of lithium ion battery, lithium ion battery and manufacturing method | 重庆市紫建电子股份有限公司 | 2021-01-05 | — | — | CN | claimed |
| CN-112042016-A | Lithium cobalt oxide secondary battery comprising fluorinated electrolyte and positive electrode material for high voltage applications | 尤米科尔公司 | 2020-12-04 | — | — | CN | claimed |
| CN-111512488-A | Non-aqueous electrolyte composition comprising lithium bis (fluorosulfonyl) imide | 索尔维公司 | 2020-08-07 | — | — | CN | claimed |
| CN-112687952-B | Electrolyte, electrochemical device, and electronic device | 宁德新能源科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-112042016-B | Lithium cobalt oxide secondary battery for high voltage applications comprising a fluorinated electrolyte and a positive electrode material | 尤米科尔公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023081612-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | Karuna Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| CN-114762170-A | Electrolyte compositions with fluorinated acyclic carbonates and fluorinated cyclic carbonates | 索尔维公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-3968971-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | Cancer Prevention Pharmaceuticals, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114142085-A | Non-aqueous electrolyte of lithium ion battery, lithium ion battery and preparation method of lithium ion battery | 重庆市紫建新能源有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-112186247-A | Non-aqueous electrolyte of lithium ion battery, lithium ion battery and manufacturing method | 重庆市紫建电子股份有限公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-112042015-A | Ni-based lithium ion secondary battery comprising fluorinated electrolyte | 尤米科尔公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-112042016-A | Lithium cobalt oxide secondary battery comprising fluorinated electrolyte and positive electrode material for high voltage applications | 尤米科尔公司 | 2020-12-04 | — | — | CN | disclosed |
| WO-2020236562-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-3368029-A1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | Cancer Prevention Pharmaceuticals, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075576-A1 | EFLORNITHINE AND SULINDAC, FIXED DOSE COMBINATION FORMULATION | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-7345192-B2 | Reduction of hair growth | THE GILLETTE COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060067903-A1 | Using 2-difluoromethylornithine | THE GILLETTE COMPANY, A DELAWARE CORPORATION | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067903-A1 | Using 2-difluoromethylornithine | FGF2, FGF1, KRT18 | LMNA 4617/4885NFKB1 3293/4885TSHR 2423/4885 |
| US-11534434-B2 | Xanomeline derivatives and methods for treating neurological disorders | CHRM1, RXFP3, NPY5R | LMNA 1087/4885NFKB1 3175/4885TSHR 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.